Lenvatinib mesylate was shown to improve overall survival in patients with unresectable liver cancer.
Eisai will participate in a global partnership of pharmaceutical companies to help accelerate access to health care in low and middle-income countries.
The collaboration taps on Keio University's strengths in iPS technology and supercentenarian research.
The acquisition of Liaoning gives Eisai a foothold in China's generics sector which accounts for 80 percent of the country's pharmaceutical market.
DNDi has formed a consortium with four pharmaceutical companies to hasten the development of drugs for leishmaniasis and Chagas disease.
Requests for clinical trial data will be assessed by an independent review panel and the results released will be anonymized.